anti-ctla-4 and anti-pd-1 immunotherapies repress tumor progression through independent cellular mechanisms

Poster presented at 4th Annual Advances in Immuno-Oncology Congress 2019 | London | UK May 20-21, 2019.

Recently, immunotherapies demonstrate robust efficacy gains and durable responses in a wide variety of cancers. Nevertheless many patients still present resistance to immunotherapies. Response to immunotherapy relies on dynamic interactions between tumor cells and the tumor micro environment through targeting immune cells using “checkpoints” molecules, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1). An improved comprehension of the basic mechanisms underlying tumor-immune system interactions may improve clinical management of cancer. Here, we report a preclinical strategy developed in Porsolt to test two FDA-approved drugs, e.g. anti-CTLA-4 and anti-PD-1. We demonstrate that the two antibodies can affect differently the tumor immune microenvironment even if they both display efficient anticancer activity.

Download this document

Filetype : PDF | 253Ko